Patient-specific immunotherapy for solid tumors that designs and manufactures individualized vaccines targeting 30 unique tumor antigens per patient. Approach uses tumor immunopeptidome mass spectrometry plus an AI platform retrained per patient to select targets and enable GMP manufacturing for clinical deployment.